Drug class
Activin A-neutralising human monoclonal antibody; activin A/ALK2 pathway inhibitor
Mechanism of action
Binds activin A and prevents activation of the abnormal ACVR1/ALK2 signalling pathway implicated in fibrodysplasia ossificans progressiva (FOP), reducing formation of heterotopic bone and disease flare-ups.
General use cases
- Reduction of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) under the US FDA PASATRU indication (approved 19 August 2026)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
